[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company expects to record a loss in the first half of 2025, with the loss expanding year-on-year, while operating revenue declines compared to the same period last year and basic earnings per share loss increases - The performance forecast covers the period from January 1, 2025, to June 30, 2025[2](index=2&type=chunk) Performance Forecast Summary | Item | Current Period (2025H1) | Prior Period (2024H1) | Change | | :--- | :--- | :--- | :--- | | Operating Revenue | **100.13 million yuan** | **137.39 million yuan** | ↓ 27.1% | | Net Profit Attributable to Shareholders of Listed Company | Loss: **approx. -89.21 million yuan** | Loss: **-72.98 million yuan** | Loss expanded by 22.2% | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: **approx. -88.91 million yuan** | Loss: **-78.37 million yuan** | Loss expanded by 13.4% | | Basic Earnings Per Share | Loss: **approx. -0.0911 yuan/share** | Loss: **-0.0745 yuan/share** | Loss expanded | [Pre-Audit Status of Performance Forecast](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E9%A2%84%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) The financial data disclosed in this performance forecast are preliminary results from the company's internal calculations and have not been audited by a certified public accountant - The financial data related to this performance forecast have not been audited by a certified public accountant[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company's performance changes are primarily influenced by the seasonal nature of its business, exhibiting a 'lower in the first half, higher in the second half' pattern, with first-half revenue and profit remaining at annual lows despite ongoing focus on 'Three Medical Synergies' reform and health big data application and service innovation - The company's business exhibits significant seasonality, generally showing a 'lower in the first half, higher in the second half' trend, leading to performance pressure in the first half[4](index=4&type=chunk) - The company's strategic core revolves around the 'Healthy China' and 'Three Medical Synergies' reforms, focusing on the 'collection, integration, and utilization' of health big data, with an emphasis on medical insurance fund management, healthcare quality and safety, pharmaceutical and medical device regulation, and health service innovation[4](index=4&type=chunk) [Risk Warning](index=1&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company explicitly states that this performance forecast data is a preliminary estimate by the finance department, unaudited, and the final accurate financial data will be disclosed in the 2025 semi-annual report, advising investors to make cautious decisions - This performance forecast data is a preliminary estimate by the company's finance department, unaudited by a certified public accountant, and thus subject to uncertainty[5](index=5&type=chunk) - The company reminds investors to rely on the detailed financial data disclosed in the 2025 semi-annual report for decision-making, exercise caution, and be aware of investment risks[5](index=5&type=chunk)[6](index=6&type=chunk)

Core Viewpoint - Guoxin Health's stock price has increased by 3.08% to 10.72 yuan as of July 11, 2025, with a total market capitalization of 10.52 billion yuan [1][2] Company Announcement Summary - Guoxin Health's controlling shareholder, Zhonghai Heng Industrial Development Co., Ltd., and its concerted party, Guoxin Development Investment Management Co., Ltd., announced a share buyback plan on April 8, 2025, intending to purchase between 100 million yuan and 200 million yuan worth of shares within six months [1][2] - As of July 8, 2025, the buyback plan is halfway through, but no shares have been purchased yet. The company will comply with legal requirements for information disclosure [2] - The buyback plan is in accordance with relevant laws and regulations, and it will not affect the company's stock distribution or control structure [2]

Market Overview - The Shanghai Composite Index closed at 3546.50 points, above the annual line, with a gain of 1.05% [1] - The total trading volume of A-shares reached 10310.63 billion yuan [1] Stocks Breaking Annual Line - A total of 55 A-shares have broken above the annual line today, with notable stocks including XWANDA, Fuxing Co., and Guolian Minsheng, showing divergence rates of 5.64%, 3.70%, and 3.15% respectively [1] - Stocks with smaller divergence rates that just crossed the annual line include Wangfujing, Tonghe Pharmaceutical, and Sanxia Water Conservancy [1] Top Stocks by Divergence Rate - The top three stocks with the highest divergence rates are: - XWANDA (9.13% increase, 5.12% turnover rate, latest price 21.16 yuan, divergence rate 5.64%) [1] - Fuxing Co. (4.31% increase, 5.52% turnover rate, latest price 2.42 yuan, divergence rate 3.70%) [1] - Guolian Minsheng (6.66% increase, 3.68% turnover rate, latest price 11.21 yuan, divergence rate 3.15%) [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Tuoer Si (3.05% increase, 3.72% turnover rate, latest price 18.56 yuan, divergence rate 2.82%) [1] - ST Huaming (4.83% increase, 10.28% turnover rate, latest price 10.21 yuan, divergence rate 2.73%) [1] - Green Beauty (3.01% increase, 2.26% turnover rate, latest price 6.50 yuan, divergence rate 2.32%) [1]

Core Viewpoint - The announcement details the progress of the shareholding increase plan by the controlling shareholder and its concerted parties, indicating that no shares have been purchased yet despite the plan being halfway through its timeline [2][3]. Group 1: Shareholding Increase Plan - The controlling shareholder, Zhonghai Heng, and its concerted party, Guoxin Development Investment Management Co., plan to increase their shareholding in the company within six months from the announcement date, with a proposed investment amount between RMB 100 million and RMB 200 million [2]. - As of July 8, 2025, the shareholding increase plan has reached its halfway point, but no shares have been acquired yet due to the parties' internal arrangements [2][3]. - The shareholding increase will comply with relevant laws and regulations, ensuring that it does not affect the company's compliance with listing conditions or lead to changes in the controlling shareholder or actual controller [3]. Group 2: Regulatory Compliance - The shareholding increase plan adheres to the Company Law, Securities Law, and other relevant regulations, as well as the business rules of the Shenzhen Stock Exchange [2][3]. - The company will continue to monitor the progress of the shareholding increase plan and fulfill its information disclosure obligations in accordance with the Shenzhen Stock Exchange's regulations [3].

证券简称：国新健康 证券代码：000503 编号：2025-47 1、国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日披露了《关于控股股东及其一致行动人增持股份计划的公告》（公告编号： 2025-16），公司控股股东中海恒实业发展有限公司（以下简称"中海恒"）及 其一致行动人国新发展投资管理有限公司（以下简称"国新发展"）计划在自公 告之日起 6 个月内，通过集中竞价等深圳证券交易所允许的方式增持公司股份， 拟增持金额不低于人民币 1 亿元，不超过人民币 2 亿元。 2、截至本公告披露日，前述增持计划时间已过半，增持主体根据自身的统 筹安排，暂未增持公司股份，将在后续的增持计划期间严格按照法律法规的相关 要求，及时履行信息披露告知义务。 近日，公司接到控股股东中海恒及其一致行动人国新发展《关于股份增持计 划时间过半的实施情况告知函》，现将相关情况公告如下： 国新健康保障服务集团股份有限公司 关于控股股东及其一致行动人增持股份计划实施进展暨增持时 间过半的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （二） ...

Core Viewpoint - The implementation of drug traceability codes starting from July 1, 2025, is expected to enhance the traceability of medical insurance drugs, strengthen drug circulation supervision, and have a profound impact on the pharmaceutical industry chain, including production, circulation, retail, and medical insurance [1][5][6]. Group 1: Implementation and Impact - The National Medical Insurance Administration has mandated that drug traceability codes must be scanned for medical insurance fund settlement starting July 1, 2025, with full collection and upload of traceability codes required by January 1, 2026 [1][5]. - The traceability code serves as an "electronic ID" for each box of medicine, ensuring unique scanning records to prevent counterfeit drugs and ensure proper drug flow [2][5]. - The traceability system is expected to reduce channel management costs by over 20% and improve operational efficiency by over 30% for companies that fully implement data uploads [3]. Group 2: Industry Response - Several listed companies are actively responding to the regulatory changes, showcasing their efforts in drug traceability and related fields [3][4]. - Companies like Guizhou Xinbang Pharmaceutical have reported significant improvements in procurement, production, storage, and circulation processes due to the new traceability platform [3]. - National Health has emphasized its commitment to data integration and service upgrades to support the traceability initiative, indicating a deep layout in drug regulatory information technology [4]. Group 3: Regulatory and Financial Implications - The traceability code is expected to enhance transparency in drug circulation, reduce logistics costs, and promote fair competition based on quality, price, and service [6][7]. - The integration of traceability data is anticipated to facilitate innovative regulatory models and improve the precision of medical insurance management [6][7]. - The shift towards data-driven credit assessments in the pharmaceutical supply chain is expected to alleviate financing challenges for pharmaceutical companies and foster diverse financial products [7].

Core Insights - GuoXin Health launched the "Tianshu·SanYi" large model and "Lingxi" intelligent platform, focusing on the integration of healthcare, medical insurance, and pharmaceuticals, marking a new phase in the digital transformation of the healthcare industry [1] - The initiative is driven by the State Council's "Artificial Intelligence+" action plan, leveraging over 20 years of industry experience and a service network covering more than 200 medical insurance clients, 800 hospitals, and over 20 drug regulatory agencies [1] Group 1 - The "Tianshu·SanYi" model addresses industry bottlenecks through four core capabilities: knowledge system foundation, professional knowledge graph empowerment, business insights navigation, and A2A global orchestration [2] - The knowledge system is built on high-quality datasets accumulated over two decades, establishing a "SanYi brain" knowledge hub that enhances the model's cognitive abilities [2] - The professional knowledge graph includes 3.55 million entity nodes and 150 million triples, enabling intelligent mapping of treatment norms, medication rules, and medical insurance policies [2] Group 2 - The model features four distinct characteristics: a growing model that supports real-time data updates and decision-making, a more accurate model with a hallucination rate below 3%, a customer-centric model that incorporates specialized knowledge, and a collaborative model that enhances operational efficiency [3] - The "Lingxi" platform focuses on integrating healthcare, medical insurance, and pharmaceutical services, creating a matrix of intelligent applications to reshape business processes and drive industry innovation [3]

Group 1 - The core viewpoint of the article highlights a significant increase in the performance of medical information technology concept stocks, with notable gains in specific companies [1] - Weining Health experienced a rise of over 10%, indicating strong market interest and investor confidence in the sector [1] - Other companies such as Dian Diagnostics and Chuangye Huikang also saw increases of over 5%, reflecting a broader positive trend in the medical information technology industry [1] Group 2 - Additional companies that followed the upward trend include Sichuang Medical, Guoxin Health, Jiuyuan Yinhai, Wanda Information, and Saili Medical, showcasing a collective movement within the sector [1]

Group 1 - The 2024 Annual General Meeting of the company was held on June 26, 2025, in Beijing, combining on-site and online voting [4][3] - A total of 412 shareholders participated in the voting, representing 291,022,880 shares, which accounts for 29.6565% of the total voting shares [5] - The meeting was convened by the board of directors and chaired by Chairman Li Yonghua [4] Group 2 - All proposals presented at the meeting were approved without any rejections [2] - The voting results for the 2024 Annual Report showed 99.7999% approval from the total voting shares [8] - The proposal for the 2024 financial settlement report received 99.5719% approval from the total voting shares [14] Group 3 - The company plans to repurchase and cancel 1,951,260 shares of restricted stock due to unmet performance targets for 2024 [35] - Following the repurchase, the total share capital will decrease from 981,312,532 shares to 979,361,272 shares [36] - Creditors have the right to claim their debts within 30 days of receiving notice of the share repurchase [37]

Core Viewpoint - The company has approved the repurchase and cancellation of 1,951,260 restricted shares as part of its first phase of the restricted stock incentive plan, which will lead to a reduction in registered capital [1][2]. Group 1 - The company held its annual general meeting on June 26, 2025, where the proposal for the repurchase and cancellation of remaining restricted shares was approved [1]. - The repurchase will be conducted at the lower of the grant price or the market price at the time of repurchase, as stipulated in the incentive plan [1]. - The total number of shares to be repurchased and canceled is 1,951,260, which will affect the company's total share capital [1]. Group 2 - The repurchase and cancellation of shares will result in a decrease in the company's registered capital, and creditors have the right to claim their debts within specified timeframes [2]. - Creditors can submit their claims via mail, fax, or email, and must provide valid proof of their claims [2]. - The company will follow legal procedures for the cancellation of the repurchased shares [2].